$12M Upfront, Up to $134M Milestones: Kyorin Licenses Edesa's ARDS Drug for Japan
EDSA has more than doubled off its 52-week low of $0.72.
Summary
Edesa signed an exclusive Japan development and commercialization deal with Kyorin Pharmaceutical for paridiprubart in ARDS. Edesa gets $12 million upfront, up to roughly $134 million in development, regulatory and sales milestones, and tiered double-digit royalties on Japanese net sales; Kyorin funds the Japan development and commercialization work and Edesa supplies the product. The cash matters immediately: the Q3 10-Q carried a going concern warning that current resources would not fund operations through fiscal 2026, and this upfront is a meaningful chunk of a company with a market cap under $30 million. It also validates the asset — paridiprubart showed a statistically significant 28-day mortality benefit in a Phase 3 ARDS study (39% versus 52% adjusted mortality risk, p<0.001) — and brings in a partner with a respiratory sales footprint in one of the world's largest pharma markets. Edesa keeps all rights outside Japan, and Kyorin holds a right of first negotiation for acute kidney injury. Watch for the U.S. government-funded ARDS platform study readout and the EB06 vitiligo Phase 2 enrollment that the October FDA IND clearance enabled.
At the time of this announcement, EDSA was trading at $2.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.9M. The 52-week trading range was $0.72 to $20.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.